Cardiac involvement in hereditary-transthyretin related amyloidosis

Amyloid

Volumn 19, Issue SUPPL. 1, 2012, Pages 16-21

  Rapezzi, Claudio ^a   Longhi, Simone ^a   Milandri, Agnese ^a   Lorenzini, Massimiliano ^a   Gagliardi, Christian ^a   Gallelli, Ilaria ^a   Leone, Ornella ^a   Quarta, Candida Cristina ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

"hypertrophy"; Cardiomyopathy; Familial amyloidosis; Heterogeneity; Transthyretin

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMIODARONE; APROTININ; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIFLUNISAL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GADOLINIUM; IODINE 123; PREALBUMIN; TAFAMIDIS; TECHNETIUM 99M;

ABDOMINAL FAT; AMYLOID NEUROPATHY; ANTICOAGULANT THERAPY; BRADYCARDIA; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR GENE THERAPY; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DEFIBRILLATOR; DIASTOLIC DYSFUNCTION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ECG ABNORMALITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ENDEMIC DISEASE; ENVIRONMENTAL FACTOR; FAMILIAL AMYLOIDOSIS; FATIGUE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HEART AMYLOIDOSIS; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE WALL; HEART MUSCLE BIOPSY; HEART OUTPUT; HEART STROKE VOLUME; HEART TRANSPLANTATION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEREDITARY TRANSTHYRETIN RELATED AMYLOIDOSIS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; HYPOTENSION; IMMUNOHISTOCHEMISTRY; LIVER TRANSPLANTATION; MASS SPECTROMETRY; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PACEMAKER; PERICARDIAL EFFUSION; PHENOTYPE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; RISK FACTOR; RNA INTERFERENCE; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SINUS RHYTHM; SUDDEN DEATH; SYNCOPE; TISSUE DOPPLER IMAGING; VENOUS CONGESTION;

AMYLOIDOSIS; CARDIOMYOPATHIES; HEART; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MUTATION; PREALBUMIN;

EID: 84861418965     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2012.673185     Document Type: Conference Paper

References (34)

1. Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952;75:408-427.
2. Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 2010;7:398-408.
3. Planté-Bordeneuve V, Ferreira A, Lalu T, Zaros C, Lacroix C, Adams D, Said G. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 2007;69:693-698. (Pubitemid 47256013)
4. Rapezzi C, Perugini E, Salvi F, Grigioni F, Riva L, Cooke RM, Ferlini A, et al. Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: towards tailoring of therapeutic strategies? Amyloid 2006;13:143-153. (Pubitemid 44630057)
5. Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, Pepys MB, Hawkins PN. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786-1791. (Pubitemid 34586914)
6. Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis 2010;52:347-361.
7. Herlenius G, Wilczek HE, Larsson M, Ericzon BG; Familial Amyloidotic Polyneuropathy World Transplant Registry. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004;77:64-71. (Pubitemid 38116874)
8. Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW. the transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a Regulatory-Agency-Approved Drug. J Mol Biol 2012.
9. Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005;62:1057-1062. (Pubitemid 41043725)
10. Conceiçäo I, De Carvalho M. Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late-and early-onset cases in Portugal. Muscle Nerve 2007;35:116-118. (Pubitemid 46052658)
11. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007;36:411-423. (Pubitemid 47512065)
12. Ikeda S, Nakazato M, Ando Y, Sobue G. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology 2002;58:1001-1007. (Pubitemid 34298536)
13. Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997;336:466-473. (Pubitemid 27074357)
14. Koeppen AH, Wallace MR, Benson MD, Altland K. Familial amyloid polyneuropathy: alanine-for-threonine substitution in the transthyretin (prealbumin) molecule. Muscle Nerve 1990;13:1065-1075. (Pubitemid 20356218)
15. Mak CM, Kwong YL, Lam CW, Chan SC, Lo CM, Fan ST, Chang CM, et al. Identification of a novel TTR Gly67Glu mutant and the first case series of familial transthyretin amyloidosis in Hong Kong Chinese. Amyloid 2007;14:293-297. (Pubitemid 350035581)
16. Perfetto F, Cappelli F, Bergesio F. Asymptomatic homozygous gene carrier in a family with Ile68Leu ATTR amyloidosis: a new endemic region in northern Tuscany? J Cardiovasc Med (Hagerstown) 2011;12:450-451.
17. Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellié C, Planté-Bordeneuve V. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 2008;15:181-186.
18. Bonaïti B, Alarcon F, Bonaïti-Pellié C, Planté-Bordeneuve V. Parentof-origin effect in transthyretin related amyloid polyneuropathy. Amyloid 2009;16:149-150.
19. Rapezzi C, Riva L, Quarta CC, Perugini E, Salvi F, Longhi S, Ciliberti P, et al. Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid 2008;15:40-48. (Pubitemid 351238493)
20. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120: 1203-1212.
21. Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol 1982;49:9-13. (Pubitemid 12003501)
22. Rahman JE, Helou EF, Gelzer-Bell R, Thompson RE, Kuo C, Rodriguez ER, Hare JM, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 2004;43:410-415. (Pubitemid 38167701)
23. Quarta CC, Borghi C, Perlini S, Musca F, Salinaro F, Longhi S, Ob ici L, et al. A simple voltage/mass index improves diagnosis of cardiac amyloidosis in patients with unexplained left ventricular hypertrophy: an electrocardiographic and echocardiographic study of more than 500 patients. Circulation 2010;122:Abstact 16852.
24. Sun JP, Stewart WJ, Yang XS, Donnell RO, Leon AR, Felner JM, Thomas JD, Merlino JD. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol 2009;103:411-415.
25. Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007;50:2101-2110. (Pubitemid 350117349)
26. Koyama J, Davidoff R, Falk RH. Longitudinal myocardial velocity gradient derived from pulsed Doppler tissue imaging in AL amyloidosis: a sensitive indicator of systolic and diastolic dysfunction. J Am Soc Echocardiogr 2004;17:36-44. (Pubitemid 38064113)
27. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186-193. (Pubitemid 40139730)
28. Glaudemans AW, Slart RH, Zeebregts CJ, Veltman NC, Tio RA, Hazenberg BP, Dierckx RA. Nuclear imaging in cardiac amyloidosis. Eur J Nucl Med Mol Imaging 2009;36:702-714.
29. Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, Ferlini A, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2- propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 2011;38:470-478.
30. Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, Ferlini A, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2011;4:659-670.
31. Rosenzweig M, Landau H. Light chain (AL) amyloidosis: update on diagnosis and management. J Hematol Oncol 2011;4:47.
32. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 1997;78:74-82. (Pubitemid 27346885)
33. Kristen AV, Dengler TJ, Hegenbart U, Schonland SO, Goldschmidt H, Sack FU, Voss F, et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 2008;5:235-240.
34. Arpesella G, Chiappini B, Marinelli G, Mikus PM, Dozza F, Pierangeli A, Magelli C, et al. Combined heart and liver transplantation for familial amyloidotic polyneuropathy. J Thorac Cardiovasc Surg 2003;125:1165-1166. (Pubitemid 36644899)